NASDAQ:ORIC ORIC Pharmaceuticals (ORIC) Stock Price, News & Analysis → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free ORIC Stock Alerts $8.99 -0.51 (-5.37%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$8.87▼$9.8750-Day Range$7.67▼$16.0352-Week Range$4.91▼$16.65Volume242,533 shsAverage Volume439,193 shsMarket Capitalization$606.11 millionP/E RatioN/ADividend YieldN/APrice Target$20.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get ORIC Pharmaceuticals alerts: Email Address ORIC Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside122.5% Upside$20.00 Price TargetShort InterestBearish15.19% of Shares Sold ShortDividend StrengthN/ASustainability-0.77Upright™ Environmental ScoreNews Sentiment0.63Based on 24 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.69) to ($1.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.14 out of 5 starsMedical Sector159th out of 921 stocksPharmaceutical Preparations Industry60th out of 428 stocks 4.5 Analyst's Opinion Consensus RatingORIC Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageORIC Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ORIC Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.19% of the outstanding shares of ORIC Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverORIC Pharmaceuticals has a short interest ratio ("days to cover") of 17.8, which indicates bearish sentiment.Change versus previous monthShort interest in ORIC Pharmaceuticals has recently increased by 8.70%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldORIC Pharmaceuticals does not currently pay a dividend.Dividend GrowthORIC Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreORIC Pharmaceuticals has received a 72.62% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for ORIC Pharmaceuticals is -0.77. Previous Next 3.1 News and Social Media Coverage News SentimentORIC Pharmaceuticals has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for ORIC Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest3 people have searched for ORIC on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ORIC Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.55% of the stock of ORIC Pharmaceuticals is held by insiders.Percentage Held by Institutions95.05% of the stock of ORIC Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ORIC Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ORIC Pharmaceuticals are expected to decrease in the coming year, from ($1.69) to ($1.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ORIC Pharmaceuticals is -4.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ORIC Pharmaceuticals is -4.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioORIC Pharmaceuticals has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ORIC Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. About ORIC Pharmaceuticals Stock (NASDAQ:ORIC)ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Read More ORIC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ORIC Stock News HeadlinesMay 11, 2024 | americanbankingnews.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) to Post Q1 2025 Earnings of ($0.47) Per Share, HC Wainwright ForecastsMay 10, 2024 | americanbankingnews.comAnalysts Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) PT at $20.00May 11, 2024 | Gold Safe Exchange (Ad)Gold Set to EXPLODE!Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.May 9, 2024 | americanbankingnews.comWedbush Weighs in on ORIC Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:ORIC)May 9, 2024 | americanbankingnews.comCitigroup Lowers ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target to $14.00May 8, 2024 | markets.businessinsider.comBuy Rating on Oric Pharmaceuticals Amidst Strong Financials and Promising Clinical PipelineMay 8, 2024 | morningstar.comORIC Pharmaceuticals IncMay 8, 2024 | finance.yahoo.comWe Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business GrowthMay 11, 2024 | Gold Safe Exchange (Ad)Gold Set to EXPLODE!Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.May 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Oric Pharmaceuticals Amid Promising Clinical Data and Strong Financial PositionMay 7, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Stoke Therapeutics (STOK), Oric Pharmaceuticals (ORIC)May 6, 2024 | investorplace.comORIC Stock Earnings: ORIC Pharmaceuticals Beats EPS for Q1 2024May 6, 2024 | globenewswire.comORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational UpdatesMay 3, 2024 | globenewswire.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 15, 2024 | globenewswire.comORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLCApril 8, 2024 | globenewswire.comORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual MeetingApril 5, 2024 | globenewswire.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 4, 2024 | globenewswire.comORIC Pharmaceuticals to Participate in Upcoming Investor ConferencesMarch 29, 2024 | seekingalpha.comORIC Pharmaceuticals: Rally Seems OverdoneMarch 21, 2024 | markets.businessinsider.comOric Pharmaceuticals: Sustained Buy Rating Amid Strong Financials and Upcoming CatalystsMarch 14, 2024 | investing.comORIC Pharmaceuticals stock target raised to $17 on strong prospectsMarch 13, 2024 | seekingalpha.comORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To GainsMarch 12, 2024 | finance.yahoo.comORIC Pharmaceuticals Inc (ORIC) Reports Q4 and Full Year 2023 Financial ResultsMarch 12, 2024 | markets.businessinsider.comThese Analysts Revise Their Forecasts On ORIC Pharmaceuticals After Q4 ResultsMarch 11, 2024 | msn.comORIC Pharmaceuticals GAAP EPS of -$0.49March 11, 2024 | globenewswire.comORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational UpdatesMarch 8, 2024 | finance.yahoo.comORIC Pharmaceuticals Inc CEO Jacob Chacko Sells 40,000 SharesSee More Headlines Receive ORIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ORIC Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2024Today5/10/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ORIC CUSIPN/A CIK1796280 Webwww.oricpharma.com Phone650-388-5600FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$20.00 High Stock Price Target$27.00 Low Stock Price Target$14.00 Potential Upside/Downside+122.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-100,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.71% Return on Assets-38.55% Debt Debt-to-Equity RatioN/A Current Ratio10.39 Quick Ratio10.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.33 per share Price / Book2.70Miscellaneous Outstanding Shares67,420,000Free Float63,680,000Market Cap$606.11 million OptionableOptionable Beta1.19 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Richard A. Heyman Ph.D. (Age 67)Co-Founder, Independent Chairman & Member of Scientific Advisory Board Comp: $93kDr. Jacob M. Chacko M.B.A. (Age 45)M.D., President, CEO & Director Comp: $921.32kMr. Dominic G. Piscitelli CPA (Age 49)M.B.A., Chief Financial Officer Comp: $636.91kDr. Pratik S. Multani M.D. (Age 57)M.S., Chief Medical Officer Comp: $686.88kDr. Charles L. Sawyers B.A. (Age 65)M.D., Ph.D., Co-Founder & Member of Scientific Advisory Board Dr. Scott W. Lowe Ph.D.Co-Founder & Member of Scientific Advisory BoardDr. Lori Sickels Friedman Ph.D. (Age 60)Chief Scientific Officer Dr. Christian V. Kuhlen Esq. (Age 51)J.D., M.D., General Counsel Mr. Daniel IazzettiVP & Head of PeopleDr. Edna Chow Maneval (Age 64)Senior Vice President of Clinical Development More ExecutivesKey CompetitorsLyell ImmunopharmaNASDAQ:LYELPharming GroupNASDAQ:PHARZymeworksNYSE:ZYMESilence TherapeuticsNASDAQ:SLNOlema PharmaceuticalsNASDAQ:OLMAView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 629,536 shares on 5/10/2024Ownership: 4.275%Monaco Asset Management SAMSold 150,000 shares on 5/9/2024Ownership: 0.193%ProShare Advisors LLCBought 11,733 shares on 5/8/2024Ownership: 0.017%China Universal Asset Management Co. Ltd.Bought 6,617 shares on 4/29/2024Ownership: 0.019%Tower Research Capital LLC TRCBought 1,517 shares on 2/13/2024Ownership: 0.014%View All Insider TransactionsView All Institutional Transactions ORIC Stock Analysis - Frequently Asked Questions Should I buy or sell ORIC Pharmaceuticals stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ORIC Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ORIC shares. View ORIC analyst ratings or view top-rated stocks. What is ORIC Pharmaceuticals' stock price target for 2024? 6 Wall Street analysts have issued 1-year target prices for ORIC Pharmaceuticals' stock. Their ORIC share price targets range from $14.00 to $27.00. On average, they predict the company's stock price to reach $20.00 in the next year. This suggests a possible upside of 122.5% from the stock's current price. View analysts price targets for ORIC or view top-rated stocks among Wall Street analysts. How have ORIC shares performed in 2024? ORIC Pharmaceuticals' stock was trading at $9.20 on January 1st, 2024. Since then, ORIC stock has decreased by 2.3% and is now trading at $8.99. View the best growth stocks for 2024 here. When is ORIC Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our ORIC earnings forecast. How were ORIC Pharmaceuticals' earnings last quarter? ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) posted its earnings results on Monday, March, 11th. The company reported ($0.49) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.49). What other stocks do shareholders of ORIC Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ORIC Pharmaceuticals investors own include Pfizer (PFE), Intel (INTC), CrowdStrike (CRWD), Valero Energy (VLO), Hello Group (MOMO), ONEOK (OKE), DocuSign (DOCU), Vaxart (VXRT), Delta Air Lines (DAL) and Datadog (DDOG). When did ORIC Pharmaceuticals IPO? ORIC Pharmaceuticals (ORIC) raised $75 million in an initial public offering on Friday, April 24th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities acted as the underwriters for the IPO. Who are ORIC Pharmaceuticals' major shareholders? ORIC Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.27%), Monaco Asset Management SAM (0.19%), China Universal Asset Management Co. Ltd. (0.02%) and ProShare Advisors LLC (0.02%). Insiders that own company stock include Dominic Piscitelli, Jacob Chacko, Pratik S Multani, Richard A Heyman, Richard A Heyman and Richard H Scheller. View institutional ownership trends. How do I buy shares of ORIC Pharmaceuticals? Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ORIC) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchCollapse of the Petrodollar Colonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ORIC Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.